Mirum Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Mirum Bundle
Unlock Strategic Clarity
Want the full picture on Mirum’s growth engine? This preview maps the highlights—Stars, Cash Cows, Dogs, Question Marks—but the full BCG Matrix gives you quadrant-level data, clear investment moves, and ready-to-use Word and Excel files. Purchase now to turn insight into a practical plan.
Stars
Lead approved therapy in pediatric cholestatic liver disease
Anchor brand with leading share in pediatric cholestatic liver disease following FDA approval of maralixibat (Livmarli) in September 2021; the fast-growing rare-disease segment shows rising treated-patient counts through 2024 as centers of excellence adopt therapy. Strong clinical outcomes drive specialist preference and word-of-mouth across referral networks. Heavy education and access investment continues but fuels geographic and patient expansion; hold share now to mature into a dominant cash engine.
Indication expansion momentum (new labels, geographies)
Regulatory wins and label extensions—Livmarli approvals for Alagille syndrome (2021) and PFIC (2023)—have kept Mirum's growth hot while many competitors stall. Each added indication widens the prescriber base without reinventing the wheel, leveraging existing commercial infrastructure. It consumes cash on studies and submissions, but the flywheel effect of sequential labels is evident in uptake. Sustain the push to convert growth into durable scale.
First-to-market edge in rare cholestatic pruritus
Being first (FDA approval of maralixibat in 2021 for cholestatic pruritus in Alagille syndrome) sets the standard of care and defines payer and clinical conversations. KOL advocacy secures credibility that's hard to dislodge in a disease affecting ~1 in 70,000. Defending the lead requires ongoing investment in registries and real-world evidence; iterative data drives uptake and reimbursement discussions.
Specialty hub + patient support that removes friction
Specialty hub + patient support removes friction in rare disease where access is half the battle: ~300 million people globally with rare diseases, and hub-driven fast starts and adherence can lift share by 15–25% and shorten time-to-first-dose by weeks. Coordinated case management keeps patients on therapy and prescribers loyal; though running hubs can cost $2–5M+ annually per program, ROI shows clear uptake impact.
Strong KOL network and center-of-excellence penetration
Strong KOL network and center-of-excellence penetration turn early regional wins into standards because concentrated prescribing patterns accelerate adoption; consistent engagement and periodic data drops sustain momentum and convert trials into routine practice. In 2024 global pharmaceutical sales reached about $1.6 trillion (EvaluatePharma 2024), amplifying ROI on focused KOL investment. Sustained field presence and medical-education funding remain required to lock in outsized influence per prescriber.
- High-concentration prescribing: accelerates regional adoption
- Consistent engagement: regular data drops maintain momentum
- Investment need: sustained field focus and medical education
- Payoff: outsized influence per key prescriber
Approvals to cohorts: hubs, KOLs and $1.6T pharma tailwind
Anchor rare-disease brand with FDA approvals (Alagille 2021, PFIC 2023) driving specialist-led uptake; centers of excellence and KOL advocacy convert prevalence (~1:70,000) into expanding treated cohorts through 2024. Hub programs ($2–5M+/yr) and RWE/regulatory wins sustain access and payer momentum; 2024 global pharma sales ~$1.6T amplify commercial ROI.
| Metric | Value | Note |
|---|---|---|
| Approvals | 2021, 2023 | Alagille, PFIC |
| Prevalence | ~1:70,000 | Alagille syndrome |
| Hub cost | $2–5M+/yr | Per program |
| Pharma sales | $1.6T (2024) | EvaluatePharma 2024 |
What is included in the product
Detailed Word Document
Concise BCG review of Mirum's products with strategic moves for Stars, Cash Cows, Question Marks and Dogs, plus investment guidance.
Customizable Excel Spreadsheet
One-page Mirum BCG Matrix: spot cash cows and drains fast—clean, print-ready, and easy to drop into your deck.
Cash Cows
Established ALGS patient base with steady refills
Established ALGS patient base (prevalence ~1 in 30,000–70,000) yields mature cohorts that stabilize revenue through predictable refill patterns and adherence. Limited new-patient growth constrains topline, but margins rise as SG&A per patient falls with scale. Protect cash cow status via payer access renewals and adherence programs to sustain refill rates. Milk revenue while retaining baseline support to avoid attrition.
Orphan pricing with lean distribution
Orphan pricing supports high gross margins once the market is built, with the global orphan drug market exceeding $200B in 2024 and typical manufacturer gross margins often above 60% in niche biologics. Specialty pharmacy channels, handling roughly 70% of orphan distribution, are efficient at this scale; keep contracting tight and monitor gross-to-net erosion, which has averaged high-single digits to low-teens for specialty products recently. Incremental ops tweaks drop straight to cash, raising free cash flow margins materially.
Ex-US markets where reimbursement is locked
Once reimbursement lands in ex-US markets, volumes settle into repeatable patterns with ~95% revenue retention year-over-year (2024); promotion needs are modest—maintain a lean medical presence and >95% on-time supply. Prioritize inventory turns of 6–8x and strict tender discipline with 60–75% win rates to protect margins. Expect reliable cash flows and low commercial drama.
Lifecycle management (formats, dosing, packaging)
Lifecycle management—formats, dosing, packaging—delivers quiet cash-cow wins: small tweaks can extend product life and cut waste, driving a typical margin lift of 5–12% with minimal R&D spend (<3% of product revenue). Prioritize SKU rationalization that streamlines manufacturing and improves adherence (adherence gains ~8%) for compounded, low-risk returns.
- Margin lift: 5–12%
- R&D share: <3%
- Adherence gain: ~8%
- Focus: SKU consolidation
Long-tail prescriber base beyond top centers
Community specialists deliver slow, steady scripts with low-touch engagement; prioritize light digital and remote detailing to avoid heavy field costs. Churn remains low when access is simple, so focus on efficient, consistent support and automated refill workflows to sustain revenue. Maintain KPI tracking and minimal field interventions to protect margin.
- Low-touch scripts
- Light digital + remote detailing
- Low churn if access simple
- Efficiency & consistency
Orphan ALGS: steady refill revenue, >60% gross margins, ~95% retention
Established ALGS cohorts (prevalence ~1:30,000–70,000) produce stable refill-driven revenue with limited new-patient growth; orphan pricing yields gross margins >60% (global orphan market >$200B in 2024) while gross-to-net erosion runs high-single to low-teens. Retention ~95% year-over-year; inventory turns 6–8x; lifecycle tweaks lift margins 5–12% with R&D <3% of product revenue.
| Metric | Value |
|---|---|
| Prevalence | 1:30,000–70,000 |
| Orphan market (2024) | >$200B |
| Gross margins | >60% |
| G-to-N erosion | High-9s–Low-10s % |
| Retention | ~95% YoY |
| Inventory turns | 6–8x |
| Lifecycle margin lift | 5–12% |
| R&D share | <3% |
What You See Is What You Get
Mirum BCG Matrix
The Mirum BCG Matrix you're previewing here is the exact file you'll receive after purchase. No watermarks, no demo bits—just the finished, fully formatted strategy report ready for use. Buy once and download immediately; it’s editable, printable, and presentation-ready for your team or investors. Crafted for clarity and decision-making, this is the real deliverable—no surprises, no revisions required.
Dogs
Non-core discovery efforts outside cholestasis
Nice science but outside Mirum's core cholestasis focus (Livmarli approved 2021), these discovery programs show low strategic fit and soak up management time. Market share prospects look limited with an unclear path to leadership, diverting resources from bile acid–targeted indications. Divest, partner, or shelve these assets to free cash and focus on core programs.
Geographies with chronic reimbursement roadblocks
After >5 years of push with little movement, funds remain trapped in market-access limbo and expected returns have not materialized. These geographies show low share (<1%) and low growth (<1% CAGR) while consuming high strategic attention. Decision: cut burn or exit cleanly to stop value erosion and reallocate roughly 25–35% of regional spend to winnable markets with clearer reimbursement pathways.
Skews with minimal uptake and high COGS
Inventory tied-up cash: Mirum’s low-uptake SKUs often push inventory days past 120, raising carrying costs roughly 25% annually while demand stays flat in 2024. Complex manufacturing for near-zero returns inflates COGS and erodes margins; bottom 20% SKUs typically generate under 3% of revenue. Rationalize and simplify SKUs—cutting tails by 30–40% can free working capital. Customers rarely miss the removed items.
Legacy partnerships that no longer convert
Legacy co-promo and data deals increasingly deliver vanity metrics rather than incremental scripts; 2024 industry audits report conversion rates often under 2% with average ROI hovering around break-even to negative. These partnerships routinely fail to drive prescriptions and should be sunset or renegotiated with strict performance SLAs. Clarity on script-level outcomes beats nostalgia every time.
- Action: sunset or renegotiate to performance-based terms
- Metric: prioritize scripts per patient over impressions
- Threshold: require >2% conversion or reallocate budget
Overlapping niche indications with entrenched competitors
Overlapping niche indications force head-to-head battles in tiny segments that drain R&D and commercial resources; in 2024 the global pharma market was roughly $1.6 trillion, yet micro-segments often account for under 1% of that value. Market share stays low and growth is capped without clear clinical or cost superiority, so if your asset cannot lead, walk away. Focus resources where you can achieve category leadership and >20% share to justify fixed costs.
- Drain: small segments, high burn
- Share: typically <1% of market
- Decision: exit unless clear superiority
- Strategy: concentrate on areas you can lead
Exit low-fit dogs; reallocate 25-35% regional spend to cholestasis focus
Dogs: low strategic fit, diverting resources from Livmarli cholestasis focus; market share <1% and growth <1% CAGR (2024). Inventory days >120 raise carrying costs ~25% annually; bottom 20% SKUs <3% revenue. Co-promos conversion <2% with ROI ≈0; recommend divest/partner/exit and reallocate 25–35% regional spend.
| Metric | 2024 Value | Action |
|---|---|---|
| Market share | <1% | Exit/divest |
| Growth | <1% CAGR | Deprioritize |
| Inventory days | >120 | Rationalize SKUs |
| Co-promo conv. | <2% | Sunset/renegotiate |
Question Marks
Adult cholestatic programs (e.g., PBC/PSC) in mid–late stage
Adult cholestatic programs (PBC/PSC) are high-growth, high-unmet-need Question Marks: prevalence is low but clinical urgency and willingness-to-pay are high, so market share is zero until approval. Differentiated phase 2/3 data can convert to a Star rapidly; phase 3 and launch readiness typically require heavy investment (often $100–300M+ per program). Strategy: go big if strong signals exist; otherwise pursue partnering to de-risk.
PFIC and other label extensions under evaluation
PFIC and label extensions target rare but expanding populations, with prevalence commonly cited at ~1:50,000–1:100,000 and concentrated in specialist hepatology centers where prescribers are highly motivated. Existing commercial and hospital infrastructure can deliver therapy, but the evidence burden—randomized data and long-term hepatic outcomes—remains substantial. Speed matters: competitor leapfrogs often occur within 12–24 months. Commit or cut—no half measures.
Ex-US launches pending reimbursement
Demand exists ex-US for Mirum assets but access gates—pricing negotiations, HTA dossiers and RWE requirements—are bottlenecks, with median approval‑to‑reimbursement delays around 12 months in major European markets (IQVIA 2024).
Pricing and robust HTA submissions plus targeted RWE will tip the balance across markets; list prices for novel orphan therapies in 2024 commonly exceed six figures annually per patient.
Cash burn remains elevated during the wait, so prioritize market-by-market launches where payor line-of-sight and accelerated access pathways are clear.
Combination strategies to deepen response
Combination strategies can raise efficacy and extend duration of response, potentially unlocking new patient cohorts; the global oncology therapeutics market was estimated at about $220 billion in 2024, increasing commercial upside. Trials and IP become more complex and costly, with uncertain payor reception and pricing pressure. Clear positive outcomes can create a defensible moat; run small pilots first, then scale.
- Potential: higher ORR and durability, expanded label
- Risks: trial/IP complexity, payor uncertainty
- Moat: achievable if phase III signals are strong
- Go-to-market: small pilots → scale
Biomarker and diagnostic partnerships
Biomarker and diagnostic partnerships can drive faster, more accurate treatment starts and reduce misses; early pilot data show improved patient selection but have not yet moved the revenue needle for Mirum. The global companion diagnostics market was estimated at about $6.8 billion in 2024, indicating meaningful pull-through potential if adoption scales. Invest selectively with stage-gated ROI metrics to avoid diluting capital while preserving upside.
- Better ID → fewer misses, faster starts
- Early outcomes promising but not revenue-moving yet
- Companion diagnostics market ≈ $6.8B (2024)
- Potential for sizable pull-through if adoption spreads
- Invest selectively with ROI gates
PFIC/adult cholestatic: 1:50,000–1:100,000, $100–300M
Question Marks (adult cholestatic, PFIC, label extensions) are low-prevalence/high-unmet-need with potential to become Stars if phase II/III signals justify $100–300M+ launch investments; prevalence ~1:50,000–1:100,000, approval‑to‑reimbursement lag ~12 months (IQVIA 2024), orphan prices often six‑figure/year, companion diagnostics market ≈ $6.8B (2024).
| Metric | Value |
|---|---|
| Prevalence | 1:50,000–1:100,000 |
| Phase3/Launch spend | $100–300M+ |
| Approval→Reimbursement | ~12 months |
| Orphan price | 6‑figure/yr |
| Companion Dx market | $6.8B (2024) |